Levetiracetam-induced interstitial lung disease in a patient with advanced lung cancer. (2020)

• Record Type: Journal Article
• Authors: Sato, Shintaro; Oba, Tomohiro; Ohta, Hiroki; Tsukahara, Yuta; Kida, Gen; Tsumiyama, Emiri; Kusano, Kenji; Nishizawa, Tomotaka; Kawabe, Rie; Yamakawa, Hideaki; Akasaka, Keiichi; Amano, Masako; Matsushima, Hidekazu
• Is Part Of: Respiratory medicine case reports. Volume 31(2020)
• Publication Date: 2020
• Subjects: Drug-induced interstitial lung disease -- Levetiracetam -- Lung cancer; AED antiepileptic drug -- BALF bronchoalveolar lavage fluid -- EGFR epidermal growth factor receptor -- GGO ground-glass opacity -- ILD interstitial lung disease -- LEV levetiracetam; Respiratory organs -- Diseases -- Periodicals; Chest -- Diseases -- Periodicals; Respiratory Tract Diseases -- Periodicals; Respiratory System -- Periodicals; Chest -- Diseases; Respiratory organs -- Diseases; Electronic journals; Periodicals; 616.2
• DOI: 10.1016/j.rmcr.2020.101241
• Languages: English
• ISSNs: 2213-0071

Abstract

Abstract: An 85-year-old woman with antibiotics-resistant pneumonia after surgery for metastatic brain tumor from lung cancer was consulted to our department. Chest CT showed diffuse GGO bilaterally. BALF showed elevated ratios of lymphocytes and CD4/CD8. Tests for bacteria, mycobacteria, and fungi were negative. She improved following levetiracetam discontinuance and systemic corticosteroid administration, and we diagnosed levetiracetam-induced lung injury. Although levetiracetam is widely used, few reports of levetiracetam-induced pneumonia exist. Changes in chest images may occur after levetiracetam administration if patients have multiple risk factors for development of drug-induced interstitial lung disease. Bronchoscopy is useful for differential diagnosis if new lung lesions appear after starting levetiracetam.